New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:00 EDTAMZN, C, EBAY, HSH, TWTR, SDRL, GILD, AAPLOptions Update; June 9, 2014
iPath S&P 500 VIX Short-Term Futures up 39c to 30.74 Option volume leaders: SDRL TWTR C GILD AMZN TSLA NFLX HSH EBAY according to Track Data.
News For EBAY;AAPL;TWTR;C;GILD;HSH;AMZN;SDRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 >>
August 21, 2015
09:34 EDTTWTR, AAPLActive equity options trading on open
Active equity options trading on open: AAPL FB BAC NFLX DIS TSLA TWTR
08:11 EDTAAPLDaimler AG could collaborate with Google, Apple, Reuters says
Subscribe for More Information
06:01 EDTAAPLABI Research: Portable PC sales to remain flat in 2015, DigiTimes says
Subscribe for More Information
August 20, 2015
18:59 EDTAMZNGoogle, Amazon, private equity compete for Indian data center unit, ET says
Subscribe for More Information
18:20 EDTAMZNAuthors Group urges DOJ probe of Amazon.com, WSJ reports
Authors United group is urging the DOJ to launch an investigation into Amazon.com, claiming the company has "unprecedented power" over the book publishing market, the Wall Street Journal reports. Reference Link
16:34 EDTGILDGilead MAA for HIV regimen has been fully validated by EMA
Gilead Sciences announced that the company's Marketing Authorization Application, MAA, for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg has been fully validated and is now under evaluation by the European Medicines Agency, EMA. Emtricitabine and tenofovir alafenamide are marketed by Gilead Sciences and rilpivirine is marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The data included in the application support the use of R/F/TAF for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older. "With this validation, R/F/TAF is now the third TAF-based filing under review by the EMA as we advance a portfolio of new treatment options that may offer high efficacy and favorable safety profiles," said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. "The R/F/TAF filing also represents the next step in our collaboration with Janssen to develop HIV treatments that potentially meet the diverse needs of people living with HIV."
16:33 EDTAMZNAmazon.com to open fifth Texas fulfillment center in San Marcos
Subscribe for More Information
16:00 EDTAAPLOptions Update; August 20, 2015
iPath S&P 500 VIX Short-Term Futures up 1.49 to 17.70. Option volume leaders: AAPL BAC FB NFLX DIS INTC BABA MU
13:18 EDTAMZNAmazon.com falls, levels to watch
The shares are down 2.8% at time of writing to $517.99. The last established support level before the large bullish gap from last earnings is at $513.06. If that level is taken out on the downside, a gam fill will begin. And the chart will be left with a blow-off top formation. Resistance is at $522.62.
12:56 EDTAMZNSmall drones bringing air traffic problems in U.S., Washington Post reports
Subscribe for More Information
12:24 EDTAAPLVIX methodology for Apple up 12% to 33.29
11:12 EDTTWTRStocks with call strike movement; MU TWTR
Subscribe for More Information
10:22 EDTAAPLApple falls, levels to watch
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Subscribe for More Information
08:45 EDTAAPLApple iPhone 6S may not pressure gross margins, says Bernstein
Subscribe for More Information
06:13 EDTAAPLApple's Australian bonds raise $1.2B within two hours, SMH reports
Subscribe for More Information
06:07 EDTCSamsung Bioepis picks Citi, Goldman as lead managers for IPO, Reuters says
Samsung Bioepis has selected Citigroup (C) and Goldman Sachs (GS) as the lead managers for its planned listening on Nasdaq next year, a source tells Reuters. Morgan Stanley (MS) and Credit Suisse (CS) will also take part in the listing for Samsung's (SSNLF) biosimilar drug development arm, the source says. Reference Link
06:07 EDTAAPLApple's 12.9-inch iPad to feature displays from Sharp, DigiTimes reports
Subscribe for More Information
06:05 EDTAMZNAmazon Web Services to open data support center in London, Financial Times says
Subscribe for More Information
05:56 EDTAMZNGoogle Express to shut down two California delivery hubs, Re/code says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use